HOME >> MEDICINE >> NEWS
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer

CHICAGO, June 2, 2007 -- ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.

A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR (gemcitabine HC1 for injection) plus carboplatin (ASCO Abstract # 7517 ). The study, conducted by the Norwegian Lung Cancer Group, enrolled 446 chemonave patients with either stage IIIB or IV NSCLC. The primary purpose of the study was to evaluate if the ALIMTA-carboplatin combination provided increased quality-of-life benefits while offering comparable survival data. As such, the primary endpoint was quality of life (defined in the study as nausea/vomiting; dyspnea or a difficulty in breathing, and; fatigue) and the secondary endpoint was overall survival.

Thus far, 384 patients have been analyzed for toxicity and there were fewer patients in the ALIMTA arm who experienced Grade 3/4 thrombocytopenia or a low platelet level (48 vs. 107, p<.001); leukopenia or a lowering of leukocyte white blood cells (44 vs. 89, p<.001), and; granulocytopenia or a lowering of granulocyte white blood cells (78 vs. 98, p=.02). More patients in the GEMZAR arm received transfusion of platelets (5 vs. 19, p=.02). At this point, no difference in survival has been observed.

The patients in this study received a comparable quality-of-life benefit whether they received ALIMTA and carboplatin or GEMZAR and carboplatin, said Bjrn Henning Grnberg, M.D. of St. Olavs University Hospital in Norway and the studys principal investigat
'"/>

Contact: Neil Hochman
n.hochman@cprworldwideusa.com
212-453-2067
CPR Worldwide
2-Jun-2007


Page: 1 2 3

Related medicine news :

1. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
2. Clinical review -- A psychological approach to the management of irritable bowel syndrome
3. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
4. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
5. Clinical guidelines for blood conservation during cardiac procedures developed
6. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
7. Clinical trial coordinators need more financial conflict-of-interest training
8. Clinical studies evaluate potential treatments for mouth ulcers
9. NIH names Clinical Trial Units for the Microbicide Trials Network
10. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
11. Study in recent issue of Clinical Pediatrics helps pediatricians to understand discipline practices

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2018)... ... December 07, 2018 , ... ... critical juncture in world affairs, U.S. leadership and funding at the United Nations ... years—great strides in reducing extreme poverty and advancing global health plus meaningful reforms ...
(Date:12/6/2018)... RATON, Fla. (PRWEB) , ... December 06, 2018 ... ... those unable to cope with day-to-day life, there are alternative solutions. M.D.-formulated Relaxium ... , Relaxium Calm ’s main ingredient is Sensoril®, an extract of the ...
(Date:12/5/2018)... ... 2018 , ... Body by Ravi Plastic Surgery and Aesthetics ... to offer the BodyTitePRO treatment. Dr. Ravi Somayazula , practice founder, has ... noninvasive techniques to improve the face, breast and body. Together with his partner, ...
(Date:12/5/2018)... Ill. (PRWEB) , ... December 05, 2018 , ... ... CRO, FSP, Strategic Resourcing, and Consulting services, announced its new office location in ... will accommodate organic growth of clinical trial operations in Europe and additional in-country ...
(Date:12/5/2018)... ... December 05, 2018 , ... ... (HM). In this role, he will be responsible for the executive oversight of ... “We conducted an extensive, nationwide search for this position,” Tom Doran, president, HM ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... SIOUX FALLS, S.D. (PRWEB) , ... December 05, 2018 , ... ... of the inaugural $1 million Sanford Lorraine Cross Award. , Jean Bennett, M.D., ... an inherited form of blindness, accepted the award on Dec. 4 at Sanford Health, ...
(Date:11/29/2018)... HOLLYWOOD, Calif. (PRWEB) , ... November 29, 2018 , ... ... rehabilitation center located in North Hollywood, CA, announced today they were selected by ... California to participate in a new Volunteer Engagement Project. , The California Department ...
(Date:11/28/2018)... THE WOODLANDS, Texas (PRWEB) , ... November 28, ... ... from Rigaku Corporation has been published and is available to ... newsletter concentrating on single crystal X-ray diffraction, published by Rigaku Oxford Diffraction ...
Breaking Medicine Technology:
Cached News: